Characteristics of patients at enrollment
| Characteristics . | Total (N = 50) . |
|---|---|
| Median age (range), y | 65 (40-84) |
| Females, n (%) | 23 (46%) |
| Ethnicity, n (%) | |
| Jewish | 40 (80%) |
| Arab | 8 (16%) |
| Others | 2 (4%) |
| Median time since diagnosis (range), y | 5.3 (0.3-24.2) |
| Myeloma subtype, n (%) | |
| Heavy chain involvement | 33 (66%) |
| Light chain involvement | 42 (84%) |
| Nonsecretory | 3 (6%) |
| Myeloma presentation, n (%) | |
| Extramedullary disease | 16 (32%) |
| Plasma cell leukemia | 3 (6%) |
| Comorbidities, n (%) | |
| Cardiac | 16 (32%) |
| Pulmonary | 7 (14%) |
| Renal | 7 (14%) |
| Other malignancies | 5 (10%) |
| Type 2 diabetes | 6 (12%) |
| Amyloid | 1 (2%) |
| Hepatic | 2 (4%) |
| BM involvement, n (%) | |
| All | 29 (58%) |
| Plasma cells ≥60% | 10 (20%) |
| BCMA-expressing plasma cells (total = 47), n (%) | |
| ≥90% | 27 (57%) |
| ECOG-PS, n (%) | |
| 0 | 13 (26%) |
| 1 | 22 (44%) |
| 2 | 15 (30%) |
| R-ISS stage (total = 45), n (%) | |
| I | 13 (29%) |
| II | 26 (58%) |
| III | 6 (13%) |
| HR cytogenetic, n (%) | |
| Not including 1q gain | 12 (24%) |
| Including 1q gain | 34 (68%) |
| Del17p | 9 (18%) |
| t(14;16) | 1 (2%) |
| t(4;14) | 3 (6%) |
| 1q gain | 31 (62%) |
| Double hit (including 1q gain) | 10 (20%) |
| Previous HSCT, n (%) | 34 (68%) |
| Lymphodepletion regimen, n (%) | |
| Fludarabine/cyclophosphamide | 47 (94%) |
| Bendamustine | 3 (6%) |
| Bridging therapy, n (%) | 10 (20%) |
| Radiotherapy | 4 (8%) |
| Chemotherapy | 4 (8%) |
| Plasmapheresis/dexamethasone | 1 (2%) |
| Selenixor/bortezomib | 1 (2%) |
| Median previous lines of treatment (range) | 4 (3-13) |
| Prior BCMA–TT, n (%) | |
| Exposed | 12 (24%) |
| Belantamab mafodotin | 11 (22%) |
| Teclistamab | 2 (17%) |
| BiTE and gamma secretase inhibitor | 1 (8%) |
| Refractory | 10 (20%) |
| Prior proteasome inhibitors, n (%) | |
| Bortezomib | |
| Exposed | 50 (100%) |
| Refractory | 40 (80%) |
| Carfilzomib | |
| Exposed | 33 (66%) |
| Refractory | 28 (56%) |
| Prior IMiDs, n (%) | |
| Lenalidomide | |
| Exposed | 50 (100%) |
| Refractory | 47 (94%) |
| Pomalomide | |
| Exposed | 39 (78%) |
| Refractory | 35 (70%) |
| Prior anti-CD38 monoclonal antibodies (daratumumab), n (%) | |
| Exposed | 50 (100%) |
| Refractory | 50 (100%) |
| Drug refractoriness, n (%) | |
| Triple-class∗ exposed | 50 (100%) |
| Triple-class∗ refractory | 47 (94%) |
| Penta-drug† exposed | 25 (50%) |
| Penta-refractory† | 15 (30%) |
| Refractory to last line therapy | 46 (92%) |
| Characteristics . | Total (N = 50) . |
|---|---|
| Median age (range), y | 65 (40-84) |
| Females, n (%) | 23 (46%) |
| Ethnicity, n (%) | |
| Jewish | 40 (80%) |
| Arab | 8 (16%) |
| Others | 2 (4%) |
| Median time since diagnosis (range), y | 5.3 (0.3-24.2) |
| Myeloma subtype, n (%) | |
| Heavy chain involvement | 33 (66%) |
| Light chain involvement | 42 (84%) |
| Nonsecretory | 3 (6%) |
| Myeloma presentation, n (%) | |
| Extramedullary disease | 16 (32%) |
| Plasma cell leukemia | 3 (6%) |
| Comorbidities, n (%) | |
| Cardiac | 16 (32%) |
| Pulmonary | 7 (14%) |
| Renal | 7 (14%) |
| Other malignancies | 5 (10%) |
| Type 2 diabetes | 6 (12%) |
| Amyloid | 1 (2%) |
| Hepatic | 2 (4%) |
| BM involvement, n (%) | |
| All | 29 (58%) |
| Plasma cells ≥60% | 10 (20%) |
| BCMA-expressing plasma cells (total = 47), n (%) | |
| ≥90% | 27 (57%) |
| ECOG-PS, n (%) | |
| 0 | 13 (26%) |
| 1 | 22 (44%) |
| 2 | 15 (30%) |
| R-ISS stage (total = 45), n (%) | |
| I | 13 (29%) |
| II | 26 (58%) |
| III | 6 (13%) |
| HR cytogenetic, n (%) | |
| Not including 1q gain | 12 (24%) |
| Including 1q gain | 34 (68%) |
| Del17p | 9 (18%) |
| t(14;16) | 1 (2%) |
| t(4;14) | 3 (6%) |
| 1q gain | 31 (62%) |
| Double hit (including 1q gain) | 10 (20%) |
| Previous HSCT, n (%) | 34 (68%) |
| Lymphodepletion regimen, n (%) | |
| Fludarabine/cyclophosphamide | 47 (94%) |
| Bendamustine | 3 (6%) |
| Bridging therapy, n (%) | 10 (20%) |
| Radiotherapy | 4 (8%) |
| Chemotherapy | 4 (8%) |
| Plasmapheresis/dexamethasone | 1 (2%) |
| Selenixor/bortezomib | 1 (2%) |
| Median previous lines of treatment (range) | 4 (3-13) |
| Prior BCMA–TT, n (%) | |
| Exposed | 12 (24%) |
| Belantamab mafodotin | 11 (22%) |
| Teclistamab | 2 (17%) |
| BiTE and gamma secretase inhibitor | 1 (8%) |
| Refractory | 10 (20%) |
| Prior proteasome inhibitors, n (%) | |
| Bortezomib | |
| Exposed | 50 (100%) |
| Refractory | 40 (80%) |
| Carfilzomib | |
| Exposed | 33 (66%) |
| Refractory | 28 (56%) |
| Prior IMiDs, n (%) | |
| Lenalidomide | |
| Exposed | 50 (100%) |
| Refractory | 47 (94%) |
| Pomalomide | |
| Exposed | 39 (78%) |
| Refractory | 35 (70%) |
| Prior anti-CD38 monoclonal antibodies (daratumumab), n (%) | |
| Exposed | 50 (100%) |
| Refractory | 50 (100%) |
| Drug refractoriness, n (%) | |
| Triple-class∗ exposed | 50 (100%) |
| Triple-class∗ refractory | 47 (94%) |
| Penta-drug† exposed | 25 (50%) |
| Penta-refractory† | 15 (30%) |
| Refractory to last line therapy | 46 (92%) |
CHOP, cyclophosphamide, hydroxydaunorubicin, oncovin, prednisone; CHOEP, cyclophosphamide, hydroxydaunorubicin, oncovin, etoposide, prednisone; CRCL, creatinine clearance; DCEP, dexamethasone, cyclophosphamide, etoposide, and cisplatin; IMiDs, immunomodulatory agents; LDH, lactate dehydrogenase; PACE, cisplatin, doxorubicin, cyclophosphamide, etoposide; R-ISS, Revised International Staging System; HSCT, hematopoietic stem cell transplantation.
defined as exposed/refractory to 1 immunomodulatory agent, 1 proteasome inhibitor, and anti-CD38 monoclonal antibodies
defined as exposed/refractory to lenalidomide, pomalidomide, bortezomib, carfilzomib, and daratumumab